Biotech and Pharmaceuticals Pharmaceuticals

More

  • intuitive_surgical.jpg

    Within about a 12-hour period, two healthcare companies have blamed the pullback in hospital spending for worse-than-anticipated financial results.

  • That this stock does well during recessions is just one of many reasons it's a Mad Money favorite.

  • elan.jpg

    Don't look now, but in the first week of the new year shares of Elan stock lost nearly three-quarters of its value last year on safety concerns about the multiple sclerosis drug Tysabri, which it shares with Biogen Idec, and efficacy concerns over the Alzheimer's drug it's developing with Wyeth.

  • JandJ_NYT_ad2.jpg

    We all make mistakes. Gosh knows I've made more than a few. And a part of me hesitates to call attention to this one. I mean, you know what they say about paybacks and karma. But this one is too good a doozy to let pass.

  • pfizer_hq.jpg

    The "Financial Times" apparently got a one-on-one interview with Pfizer Chairman and CEO Jeff Kindler and is playing up what he said with the headline, "Pfizer eyes merger deal with large rival."

  • As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.

  • Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.

  • We finished the day down, but these two guys were responsible for much of the trading session’s strength, Cramer says.

  • bristol_myers_squibb.jpg

    Drugmaker Bristol-Myers Squibb said Tuesday it will eliminate another 10 percent of its work force through 2010 as it works to pare costs before it loses patent protection on key drugs.

  • pfizer_hq.jpg

    For months now several analysts have been pointing out that despite big pharma's many problems some of the companies still pay healthy dividends. And when T-bills are offering next to nothing, a solid dividend yield in these rough and tumble times is a good thing.

  • graphic_fast_money.jpg

    Pharma companies are usually considered safety plays. But might they also be growth stocks in disguise?

  • With stocks down substantially in 2008, could next year be the opportunity of a lifetime to get long?

  • lilly_hq.jpg

    CEOs of big drug companies are rarely, if ever, publicly candid about the price of their stock. You usually get the boilerplate line about how they manage the business and the market will do whatever.

  • Analysts have a one-day respite between two major pharma R & D days and they're using it to size up Merck's update yesterday and to set expectations for Eli Lilly's briefing tomorrow.

  • I wrote this morning's post from the Merck analyst meeting before sitting down for my exclusive interview with Exec Veep Ken Frazier. So, I had to pass along this fresh anecdote that illustrates even more how far this drug company and its people have come.

  • merck_HQ2.jpg

    Sitting here at Merck's annual drug research and development for the Street in the media room at the company's headquarters in central New Jersey. This year, for the first time, MRK is allowing reporters into the actual meeting room with the 300 or so analysts and investors

  • Five stocks, huge yields, great defense against this volatile market.

  • merck_sign.jpg

    Earlier this week UBS pharmaceutical analyst Roopesh Patel put out a big 2009 sector outlook research note claiming, "So far, the global economic slowdown has had no noticeable impact — a) U.S. weekly and monthly U.S. prescription trends are stable; b) there also is no meaningfully cautionary commentary from any of the companies...." Well, he might have spoken too soon.

  • pharma_new2.jpg

    Look for M&A activity—big and small—a pair of breakthrough drugs and the prospect of government price controls.

  • johnson_johnson2_logo.jpg

    Does the Food and Drug Administration approve drugs anymore? Or are we seeing the lame-duck leadership at the agency punt any action over to the next administration?